Unsafe
Not Aligned
Patient Risk:
High
Summary
The provided statements are generic product/market facts and do not reflect or accurately map to the specific FDA-approved prescribing information excerpts supplied (indications, dosing/duration limits, contraindications, warnings/precautions, pediatric use, adverse reactions). No substantive label claims were evaluated against the label, and therefore alignment to the prescribing information cannot be established.
Category Scores
Accurate Statements
Unsupported Statements
Clobetasol propionate is a corticosteroid used in topical medicines.
No support for this specific claim is present in the supplied label excerpts.
Clobetasol propionate is available in creams, ointments, lotions, and solutions.
The provided label excerpts only explicitly reference cream 0.05% (and mention other formulations generally), so this breadth of dosage forms is not supported by the supplied text.
Multiple manufacturers make clobetasol propionate across different products and strengths.
Manufacturer/market availability statements are not supported by the supplied FDA label excerpts.
Availability of clobetasol propionate depends on the country and the specific dosage form.
Country- and market-specific availability is not addressed in the supplied prescribing information excerpts.
In many markets, clobetasol propionate is available as branded products made under a specific company’s marketing authorization.
Not supported by the supplied prescribing information excerpts.
In many markets, clobetasol propionate is available as generics from multiple manufacturers once patents/exclusivity (if any) and market controls allow.
Not supported by the supplied prescribing information excerpts.
The manufacturer can change by strength or dosage form.
Not supported by the supplied prescribing information excerpts.
Different companies may produce different dosage forms or strengths of clobetasol propionate under separate product registrations.
Not supported by the supplied prescribing information excerpts.
Contradictions
Important Omissions
FDA-label-aligned specifics for cream 0.05% such as indication wording, treatment duration limits (max 2 consecutive weeks; total ≤50 g/week), occlusion restriction, contraindication language (hypersensitivity), HPA-axis suppression risk and suggested monitoring (ACTH stimulation/A.M. cortisol/urinary free cortisol), and pediatric restriction (not recommended under 12 years).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Because the statements are largely unsupported by the provided prescribing information and omit key safety-critical label elements (duration/dose limits, occlusion avoidance, HPA-axis suppression risk/monitoring, and pediatric restriction), they do not help ensure label-consistent safe use based on the supplied FDA text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Claims are generic/market-focused and not supported by the supplied FDA label excerpts; key label safety and dosing details are omitted.
Suggested Improvement
Replace generic product availability statements with specific, label-supported content from the provided excerpts (e.g., cream 0.05% indication; apply thin layer twice daily; limit to 2 consecutive weeks and ≤50 g/week; avoid occlusive dressings; contraindicated with hypersensitivity; HPA-axis suppression/Cushing’s/hyperglycemia/glucosuria risk; periodic evaluation in large-area/occluded use; pediatric under 12 not recommended).